<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Almirall Sa — News on 6ix</title>
<link>https://6ix.com/company/almirall-sa</link>
<description>Latest news and press releases for Almirall Sa on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Mon, 11 May 2026 05:18:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/almirall-sa" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo68361e4c78dffbe2df14053c.webp</url>
<title>Almirall Sa</title>
<link>https://6ix.com/company/almirall-sa</link>
</image>
<item>
<title>Almirall Continues Its Positive Trajectory in Q1 2026 in Line With Expectations – Led by 19.3% YoY Growth of Its European Dermatology Business</title>
<link>https://6ix.com/company/almirall-sa/news/almirall-continues-its-positive-trajectory-in-q1-2026-in-line-with-expectations-led-by-193percent-yoy-growth-of-its-european-dermatology-business</link>
<guid isPermaLink="true">https://6ix.com/company/almirall-sa/news/almirall-continues-its-positive-trajectory-in-q1-2026-in-line-with-expectations-led-by-193percent-yoy-growth-of-its-european-dermatology-business</guid>
<pubDate>Mon, 11 May 2026 05:18:00 GMT</pubDate>
<description>BARCELONA, May 11, 2026--Almirall, S.A. (ALM), a global pharmaceutical company dedicated to medical dermatology, today announced its financial results for the first quarter of 2026. Almirall continued to deliver on the company’s growth trajectory in line with expectations and the long-term strategy, led by 19.3% YoY growth of its European Dermatology business to €166.3 MM.</description>
</item>
<item>
<title>Evotec Announces Nomination of First Preclinical Development Candidate in Dermatology Collaboration with Almirall</title>
<link>https://6ix.com/company/almirall-sa/news/evotec-announces-nomination-of-first-preclinical-development-candidate-in-dermatology-collaboration-with-almirall</link>
<guid isPermaLink="true">https://6ix.com/company/almirall-sa/news/evotec-announces-nomination-of-first-preclinical-development-candidate-in-dermatology-collaboration-with-almirall</guid>
<pubDate>Mon, 04 May 2026 05:50:00 GMT</pubDate>
<description>Joint Evotec-Almirall team advances small molecule program to preclinical development significantly outperforming standard industry timelines Collaboration leverages Evotec's end-to-end integrated AI/ML-driven R&D capabilities and Almirall's dermatology ...</description>
</item>
<item>
<title>Almirall and Barcelona Supercomputing Center Expand Their Collaboration to Accelerate Innovation in Medical Dermatology</title>
<link>https://6ix.com/company/almirall-sa/news/almirall-and-barcelona-supercomputing-center-expand-their-collaboration-to-accelerate-innovation-in-medical-dermatology</link>
<guid isPermaLink="true">https://6ix.com/company/almirall-sa/news/almirall-and-barcelona-supercomputing-center-expand-their-collaboration-to-accelerate-innovation-in-medical-dermatology</guid>
<pubDate>Mon, 13 Apr 2026 07:00:00 GMT</pubDate>
<description>BARCELONA, Spain, April 13, 2026--Almirall, S.A. (ALM), a global biopharmaceutical company dedicated to medical dermatology, have announced an expanded collaboration with the Barcelona Supercomputing Center – Centro Nacional de Supercomputación (BSC – CNS). This new framework agreement strengthens their partnership, aiming to accelerate research and development in medical dermatology by applying advanced supercomputing, High-Performance Computing (HPC), and Artificial Intelligence.</description>
</item>
<item>
<title>Lebrikizumab delivered long-term disease control for up to four years in patients with moderate-to-severe atopic dermatitis</title>
<link>https://6ix.com/company/almirall-sa/news/lebrikizumab-delivered-long-term-disease-control-for-up-to-four-years-in-patients-with-moderate-to-severe-atopic-dermatitis</link>
<guid isPermaLink="true">https://6ix.com/company/almirall-sa/news/lebrikizumab-delivered-long-term-disease-control-for-up-to-four-years-in-patients-with-moderate-to-severe-atopic-dermatitis</guid>
<pubDate>Fri, 27 Mar 2026 13:00:00 GMT</pubDate>
<description>BARCELONA, Spain, March 27, 2026--Almirall, S.A. (ALM), a global biopharmaceutical company focused on medical dermatology, today presented positive long-term interim results from the ongoing Phase 3b ADlong study evaluating the efficacy and safety of lebrikizumab in adults and adolescents with moderate-to-severe atopic dermatitis (AD). Lebrikizumab delivered near-complete skin clearance and itch relief for up to four years for patients with moderate-to-severe atopic dermatitis, while maintaining</description>
</item>
<item>
<title>AAD 2026: Almirall Presents New Clinical and Real‑world Evidence Across Atopic Dermatitis, Psoriasis, Actinic Keratosis and Acne</title>
<link>https://6ix.com/company/almirall-sa/news/aad-2026-almirall-presents-new-clinical-and-realworld-evidence-across-atopic-dermatitis-psoriasis-actinic-keratosis-and-acne</link>
<guid isPermaLink="true">https://6ix.com/company/almirall-sa/news/aad-2026-almirall-presents-new-clinical-and-realworld-evidence-across-atopic-dermatitis-psoriasis-actinic-keratosis-and-acne</guid>
<pubDate>Thu, 26 Mar 2026 11:00:00 GMT</pubDate>
<description>DENVER, March 26, 2026--Almirall S.A. (ALM), a global biopharmaceutical company dedicated to medical dermatology, is presenting a broad range of clinical and real‑world data across its portfolio at the 2026 American Academy of Dermatology (AAD) Annual Meeting. The company’s presence includes more than 15 scientific posters, led by 9 lebrikizumab presentations in atopic dermatitis (AD), new analyses on tirbanibulin (AK), two on tildrakizumab from the POSITIVE study, and two sarecycline pooled Pha</description>
</item>
<item>
<title>Almirall's 17th Skin Academy Highlights Scientific Advances in Inflammatory Skin Diseases and Skin Cancer, Patient-Reported Outcomes, and Holistic Care in Medical Dermatology</title>
<link>https://6ix.com/company/almirall-sa/news/almiralls-17th-skin-academy-highlights-scientific-advances-in-inflammatory-skin-diseases-and-skin-cancer-patient-reported-outcomes-and-holistic-care-in-medical-dermatology</link>
<guid isPermaLink="true">https://6ix.com/company/almirall-sa/news/almiralls-17th-skin-academy-highlights-scientific-advances-in-inflammatory-skin-diseases-and-skin-cancer-patient-reported-outcomes-and-holistic-care-in-medical-dermatology</guid>
<pubDate>Mon, 23 Mar 2026 07:00:00 GMT</pubDate>
<description>BARCELONA, Spain & PRAGUE, March 23, 2026--Almirall, a global biopharmaceutical company dedicated to medical dermatology, this weekend hosted the 17th edition of Skin Academy, a premier scientific meeting for dermatologists and healthcare professionals. This year’s comprehensive scientific programme focused on sharing the latest scientific knowledge and clinical insights across a number of important skin diseases that will shape the future of medical dermatology.</description>
</item>
<item>
<title>Lebrikizumab Delivered Significant Skin Clearance and Improved Disease Severity in Children With Moderate-to-severe Atopic Dermatitis</title>
<link>https://6ix.com/company/almirall-sa/news/lebrikizumab-delivered-significant-skin-clearance-and-improved-disease-severity-in-children-with-moderate-to-severe-atopic-dermatitis</link>
<guid isPermaLink="true">https://6ix.com/company/almirall-sa/news/lebrikizumab-delivered-significant-skin-clearance-and-improved-disease-severity-in-children-with-moderate-to-severe-atopic-dermatitis</guid>
<pubDate>Mon, 16 Mar 2026 10:53:00 GMT</pubDate>
<description>BARCELONA, Spain, March 16, 2026--Almirall, S.A. (ALM), a global biopharmaceutical company focused on medical dermatology, today announced positive, top-line results from the pivotal Phase 3 ADorable-1 trial evaluating efficacy and safety of lebrikizumab for children and adolescents with moderate-to-severe atopic dermatitis aged 6 months to <18 years. Lebrikizumab met both co-primary and key secondary endpoints, delivering near-complete skin clearance, reduced disease severity, itch relief and i</description>
</item>
<item>
<title>Almirall Inaugurates Offices in China to Advance Innovation in Medical Dermatology Through Partnerships</title>
<link>https://6ix.com/company/almirall-sa/news/almirall-inaugurates-offices-in-china-to-advance-innovation-in-medical-dermatology-through-partnerships</link>
<guid isPermaLink="true">https://6ix.com/company/almirall-sa/news/almirall-inaugurates-offices-in-china-to-advance-innovation-in-medical-dermatology-through-partnerships</guid>
<pubDate>Thu, 12 Mar 2026 07:36:00 GMT</pubDate>
<description>SHANGHAI & BARCELONA, Spain, March 12, 2026--Almirall, S.A. (ALM), a global biopharmaceutical company dedicated to medical dermatology based in Barcelona, today holds an institutional event to inaugurate new offices in the Jing’an district in Shanghai, China. The presence of Almirall in Shanghai (Almirall Shanghai Pharmaceutical Consulting Co. Ltd) is dedicated to creating additional opportunities for innovation in medical dermatology, combining the company’s strong in-house R&D capabilities wit</description>
</item>
<item>
<title>etherna's intratumoral mRNA/LNP platform advances to clinical testing in nonmelanoma skin cancer led by Almirall</title>
<link>https://6ix.com/company/almirall-sa/news/ethernas-intratumoral-mrnalnp-platform-advances-to-clinical-testing-in-nonmelanoma-skin-cancer-led-by-almirall</link>
<guid isPermaLink="true">https://6ix.com/company/almirall-sa/news/ethernas-intratumoral-mrnalnp-platform-advances-to-clinical-testing-in-nonmelanoma-skin-cancer-led-by-almirall</guid>
<pubDate>Tue, 24 Feb 2026 07:00:00 GMT</pubDate>
<description>etherna, a leading provider of cutting-edge mRNA and lipid nanoparticle (LNP) technology across the biotech and pharma industry, announces that one of its key collaborators, Almirall (www.almirall.com), a leading medical dermatology company, nominated LAD116 as a novel therapy targeting non-melanoma skin cancer for further development in IND enabling studies. LAD116 is based on etherna's intratumoral mRNA/LNP platform for therapies intended to generate a potent immune response directly within th</description>
</item>
<item>
<title>Almirall’s 2025 Results</title>
<link>https://6ix.com/company/almirall-sa/news/almiralls-2025-results</link>
<guid isPermaLink="true">https://6ix.com/company/almirall-sa/news/almiralls-2025-results</guid>
<pubDate>Mon, 23 Feb 2026 06:06:00 GMT</pubDate>
<description>BARCELONA, Spain, February 23, 2026--Almirall, S.A. (ALM):</description>
</item>
<item>
<title>EpimAb Biotherapeutics Announces the First CTA Filing of a FIT-IG® Bispecific Antibody by its License Partner Almirall</title>
<link>https://6ix.com/company/almirall-sa/news/epimab-biotherapeutics-announces-the-first-cta-filing-of-a-fit-igr-bispecific-antibody-by-its-license-partner-almirall</link>
<guid isPermaLink="true">https://6ix.com/company/almirall-sa/news/epimab-biotherapeutics-announces-the-first-cta-filing-of-a-fit-igr-bispecific-antibody-by-its-license-partner-almirall</guid>
<pubDate>Tue, 10 Feb 2026 01:00:00 GMT</pubDate>
<description>SHANGHAI, Feb. 10, 2026 (GLOBE NEWSWIRE) -- EpimAb Biotherapeutics, a clinical stage biopharmaceutical company specializing in the development of novel multispecific antibodies, today announced the achievement of a first CTA Filing by Almirall (www.almirall.com) under the license agreement between the companies completed in 2023. Under the terms of the agreement, Almirall licensed EpimAb’s proprietary Fabs-In-Tandem Immunoglobulin (FIT-Ig) platform technology to generate, develop and commerciali</description>
</item>
<item>
<title>Almirall Announces the Approval of Seysara® in China for the Treatment of Moderate-to-Severe Acne</title>
<link>https://6ix.com/company/almirall-sa/news/almirall-announces-the-approval-of-seysarar-in-china-for-the-treatment-of-moderate-to-severe-acne</link>
<guid isPermaLink="true">https://6ix.com/company/almirall-sa/news/almirall-announces-the-approval-of-seysarar-in-china-for-the-treatment-of-moderate-to-severe-acne</guid>
<pubDate>Thu, 29 Jan 2026 07:00:00 GMT</pubDate>
<description>BARCELONA, Spain, January 29, 2026--Almirall, S.A. (ALM) a global pharmaceutical company dedicated to medical dermatology announced today that China’s National Medical Products Administration (NMPA) has approved Seysara® (sarecycline hydrochloride). Sarecycline hydrochloride is the first oral antibiotic that was specifically developed for use in acne and is approved for the treatment of inflammatory lesions of non-nodular moderate-to-severe acne vulgaris in patients 9 years of age and older1.</description>
</item>
<item>
<title>Almirall Announces "LumiNE", a Phase III Clinical Study Assessing the Efficacy of Lebrikizumab for the Treatment of Nummular Eczema</title>
<link>https://6ix.com/company/almirall-sa/news/almirall-announces-lumine-a-phase-iii-clinical-study-assessing-the-efficacy-of-lebrikizumab-for-the-treatment-of-nummular-eczema</link>
<guid isPermaLink="true">https://6ix.com/company/almirall-sa/news/almirall-announces-lumine-a-phase-iii-clinical-study-assessing-the-efficacy-of-lebrikizumab-for-the-treatment-of-nummular-eczema</guid>
<pubDate>Thu, 15 Jan 2026 07:00:00 GMT</pubDate>
<description>BARCELONA, Spain, January 15, 2026--Almirall, S.A. (ALM), a global pharmaceutical company dedicated to medical dermatology, announces the planned start of a phase III study assessing the efficacy and safety of Lebrikizumab (Ebglyss®, currently approved for the treatment of moderate-to-severe atopic dermatitis) in patients with nummular eczema. This study will be initiated in the first half of 2026 and is aligned with Almirall’s ambition of leadership in medical dermatology and is part of the ong</description>
</item>
<item>
<title>Almirall Presents R&D Pipeline Advances Supported by Sustained Growth and Leadership in Medical Dermatology at J.P. Morgan Healthcare Conference</title>
<link>https://6ix.com/company/almirall-sa/news/almirall-presents-r-d-pipeline-075300772</link>
<guid isPermaLink="true">https://6ix.com/company/almirall-sa/news/almirall-presents-r-d-pipeline-075300772</guid>
<pubDate>Wed, 14 Jan 2026 07:53:00 GMT</pubDate>
<description>SAN FRANCISCO, January 14, 2026--Almirall, S.A. (ALM), a global pharmaceutical company dedicated to medical dermatology, is participating in the 44th J.P. Morgan Healthcare Conference 2026, taking place from 12th to 14th January 2026 in San Francisco, to provide an update on its business strategy, pipeline advancement, and business outlook.</description>
</item>
<item>
<title>Almirall’s 2025 9M Results</title>
<link>https://6ix.com/company/almirall-sa/news/almiralls-2025-9m-results</link>
<guid isPermaLink="true">https://6ix.com/company/almirall-sa/news/almiralls-2025-9m-results</guid>
<pubDate>Mon, 10 Nov 2025 06:30:00 GMT</pubDate>
<description>BARCELONA, Spain, November 10, 2025--Almirall, S.A. (ALM) a global biopharmaceutical company based in Barcelona, today announced its financial results for the first nine months of 2025. Almirall continues to deliver its sustained growth trajectory based on strong sales performance in 9M 2025, which was mainly driven by the dermatology business, led by the biologics portfolio in Europe. Net Sales increased by 12.8% YoY to a total of €820.7 MM, EBITDA reached €180.7 MM (increase of 27.1% YoY) driv</description>
</item>
<item>
<title>RECORDATI APPOINTS MIKE MCCLELLAN AS NEW CHIEF FINANCIAL OFFICER</title>
<link>https://6ix.com/company/almirall-sa/news/recordati-appoints-mike-mcclellan-as-new-chief-financial-officer</link>
<guid isPermaLink="true">https://6ix.com/company/almirall-sa/news/recordati-appoints-mike-mcclellan-as-new-chief-financial-officer</guid>
<pubDate>Thu, 23 Oct 2025 06:32:00 GMT</pubDate>
<description>NEWS RELEASE Milan, 23 October 2025 – Recordati, a global pharmaceutical company, announces today that Mike McClellan will join as its new Chief Financial Officer (CFO) as of January 1, 2026 and will be based in the Group’s headquarters in Milan. Mike McClellan, an American national, is a seasoned CFO in the pharmaceutical industry with nearly 30 years of experience across various geographies. Most recently, he served as CFO of Almirall (2019-2025) where he played a pivotal role in delivering su</description>
</item>
<item>
<title>Almirall Presents Long‑Term Results from First Real‑World Dermatology Study Using WHO‑5 Well‑Being Index as Primary Endpoint in the treatment of Psoriasis at EADV 2025</title>
<link>https://6ix.com/company/almirall-sa/news/almirall-presents-longterm-results-from-first-realworld-dermatology-study-using-who5-wellbeing-index-as-primary-endpoint-in-the-treatment-of-psoriasis-at-eadv-2025</link>
<guid isPermaLink="true">https://6ix.com/company/almirall-sa/news/almirall-presents-longterm-results-from-first-realworld-dermatology-study-using-who5-wellbeing-index-as-primary-endpoint-in-the-treatment-of-psoriasis-at-eadv-2025</guid>
<pubDate>Thu, 18 Sep 2025 06:00:00 GMT</pubDate>
<description>PARIS, September 18, 2025--Almirall, S.A. (ALM) a global biopharmaceutical company focused on medical dermatology today announced new long-term results from the POSITIVE study, presented as a late-breaker at the 34th Congress of the European Academy of Dermatology and Venereology 2025 (EADV) in Paris.</description>
</item>
<item>
<title>EADV 2025: Almirall Advances Skin Science and Leads Innovation for Holistic Patient Care in Medical Dermatology</title>
<link>https://6ix.com/company/almirall-sa/news/eadv-2025-almirall-advances-skin-science-and-leads-innovation-for-holistic-patient-care-in-medical-dermatology</link>
<guid isPermaLink="true">https://6ix.com/company/almirall-sa/news/eadv-2025-almirall-advances-skin-science-and-leads-innovation-for-holistic-patient-care-in-medical-dermatology</guid>
<pubDate>Wed, 17 Sep 2025 06:57:00 GMT</pubDate>
<description>PARIS, September 17, 2025--Almirall, S.A. (ALM) a global biopharmaceutical company dedicated to medical dermatology, is a major contributor to the 2025 European Academy of Dermatology and Venereology Congress (EADV) presenting new data across its broad portfolio of dermatological treatments including new real-world data of lebrikizumab on atopic dermatitis, new clinical data of tildrakizumab on psoriasis and tirbanibulin on actinic keratosis. The 34th EADV congress will take place from September</description>
</item>
<item>
<title>Absci Reports Business Updates and Second Quarter 2025 Financial and Operating Results</title>
<link>https://6ix.com/company/almirall-sa/news/absci-reports-business-updates-and-second-quarter-2025-financial-and-operating-results</link>
<guid isPermaLink="true">https://6ix.com/company/almirall-sa/news/absci-reports-business-updates-and-second-quarter-2025-financial-and-operating-results</guid>
<pubDate>Tue, 12 Aug 2025 20:05:00 GMT</pubDate>
<description>Strengthened balance sheet raising approximately $64 million in gross proceeds in July 2025; cash, cash equivalents, and short-term investments now sufficient to fund operations into the first half of 2028 Expanded ongoing collaboration with Almirall, with election of a second target focused on dermatological indications VANCOUVER, Wash. and NEW YORK, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics</description>
</item>
<item>
<title>Almirall and Absci Expand AI Drug Creation Collaboration Adding a Second Dermatology Target</title>
<link>https://6ix.com/company/almirall-sa/news/almirall-and-absci-expand-ai-drug-creation-collaboration-adding-a-second-dermatology-target</link>
<guid isPermaLink="true">https://6ix.com/company/almirall-sa/news/almirall-and-absci-expand-ai-drug-creation-collaboration-adding-a-second-dermatology-target</guid>
<pubDate>Thu, 07 Aug 2025 06:00:00 GMT</pubDate>
<description>Almirall selects second target in AI Drug Creation collaborationExpanded collaboration builds on Absci’s successful de novo molecule design for difficult‑to‑drug targets in the first stage of the collaboration with Almirall BARCELONA, Spain and VANCOUVER, Wash., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Almirall (BME: ALM), a global biopharmaceutical company focused on medical dermatology, and Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutic</description>
</item>
</channel>
</rss>